Domača stran0775 • HKG
add
CK Life Sciences Intl (Holdings) Inc
Prejšnji trg. dan.
0,41 $
Dnevni razpon
0,41 $ - 0,42 $
Letni razpon
0,30 $ - 0,62 $
Tržna kapitalizacija
3,94 mrd. HKD
Povprečni obseg
887,22 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
HKG
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (HKD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,32 mrd. | 2,20 % |
Stroški poslovanja | 323,51 mio. | −4,23 % |
Čisti dohodek | 500,50 tis. | −97,29 % |
Čista dobičkovnost prihodkov | 0,04 | −97,20 % |
Earnings per share | — | — |
EBITDA | 117,12 mio. | 36,03 % |
Efektivna davčna stopnja | 79,96 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (HKD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 562,09 mio. | 11,10 % |
Skupna sredstva | 10,89 mrd. | −1,45 % |
Skupne obveznosti | 6,87 mrd. | −0,11 % |
Celoten lastniški kapital | 4,01 mrd. | — |
Shares outstanding | 9,61 mrd. | — |
Razmerje P/B | 0,98 | — |
Donosnost sredstev | 1,75 % | — |
Donosnost kapitala | 1,91 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (HKD) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 500,50 tis. | −97,29 % |
Denar iz dejavnosti | 72,70 mio. | 80,63 % |
Denar iz naložb | −47,88 mio. | −484,81 % |
Denar iz financiranja | −77,72 mio. | 41,39 % |
Neto sprememba denarnih sredstev | −57,56 mio. | 42,02 % |
Prost denarni tok | 35,56 mio. | 91,21 % |
Vizitka
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
Generalni direktor
Datum ustanovitve
2000
Spletno mesto
Zaposleni
1.968
